EUCTR2005-002524-34-IT进行中（未招募）不适用
An open label, non comparative, phase III study of the Raf Kinase Inhibitor BAY 43-9006 as a subsequent to first line therapy in patients with advanced renal cell carcinoma.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- BAYER
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell CarcinomaAdvanced Renal Cell CarcinomaEUCTR2005-002524-34-DKBAYER Healthcare AG1,500
进行中（未招募）
不适用
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell CarcinomaEUCTR2005-002524-34-BEBAYER Healthcare AG1,500
进行中（未招募）
不适用
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma - EAP (Early Access Program)EUCTR2005-002524-34-SEBAYER Healthcare AG1,500
进行中（未招募）
不适用
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell CarcinomaAdvanced Renal Cell CarcinomaEUCTR2005-002524-34-PTBAYER Healthcare AG1,500
进行中（未招募）
1 期
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma Estudio en fase III, abierto, no comparativo del inhibidor de la Raf-kinasa BAY 43-9006 como tratamiento posterior a la terapia de primera línea en pacientes con carcinoma de células renales avanzado - EU-ARCCSAdvanced Renal Cell CarcinomaEUCTR2005-002524-34-ESBAYER Healthcare AG